Literature DB >> 35491768

Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers.

Jaileene Pérez-Morales1, Hong Lu2, Wei Mu2, Ilke Tunali2,3, Tugce Kutuk4, Steven A Eschrich5, Yoganand Balagurunathan5, Robert J Gillies2, Matthew B Schabath1,6.   

Abstract

BACKGROUND: Image-based biomarkers could have translational implications by characterizing tumor behavior of lung cancers diagnosed during lung cancer screening. In this study, peritumoral and intratumoral radiomics and volume doubling time (VDT) were used to identify high-risk subsets of lung patients diagnosed in lung cancer screening that are associated with poor survival outcomes.
METHODS: Data and images were acquired from the National Lung Screening Trial. VDT was calculated between two consequent screening intervals approximately 1 year apart; peritumoral and intratumoral radiomics were extracted from the baseline screen. Overall survival (OS) was the main endpoint. Classification and Regression Tree analyses identified the most predictive covariates to classify patient outcomes.
RESULTS: Decision tree analysis stratified patients into three risk-groups (low, intermediate, and high) based on VDT and one radiomic feature (compactness). High-risk patients had extremely poor survival outcomes (hazard ratio [HR] = 8.15; 25% 5-year OS) versus low-risk patients (HR = 1.00; 83.3% 5-year OS). Among early-stage lung cancers, high-risk patients had poor survival outcomes (HR = 9.07; 44.4% 5-year OS) versus the low-risk group (HR = 1.00; 90.9% 5-year OS). For VDT, the decision tree analysis identified a novel cut-point of 279 days and using this cut-point VDT alone discriminated between aggressive (HR = 4.18; 45% 5-year OS) versus indolent/low-risk cancers (HR = 1.00; 82.8% 5-year OS).
CONCLUSION: We utilized peritumoral and intratumoral radiomic features and VDT to generate a model that identify a high-risk group of screen-detected lung cancers associated with poor survival outcomes. These vulnerable subset of screen-detected lung cancers may be candidates for more aggressive surveillance/follow-up and treatment, such as adjuvant therapy.

Entities:  

Keywords:  CART; LDCT; NLST; Radiomics; VDT; early detection

Mesh:

Year:  2022        PMID: 35491768      PMCID: PMC9310661          DOI: 10.3233/CBM-210194

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   3.828


  54 in total

1.  Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers.

Authors:  Rebecca M Lindell; Thomas E Hartman; Stephen J Swensen; James R Jett; David E Midthun; Henry D Tazelaar; Jayawant N Mandrekar
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

2.  Prognostic impact of solid-part tumour volume doubling time in patients with radiological part-solid or solid lung cancer.

Authors:  Yusuke Setojima; Yoshihisa Shimada; Takehiko Tanaka; Shunsuke Shigefuku; Yojiro Makino; Sachio Maehara; Masaru Hagiwara; Ryuichi Masuno; Takafumi Yamada; Masatoshi Kakihana; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Eur J Cardiothorac Surg       Date:  2020-04-01       Impact factor: 4.191

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  Overdiagnosis in lung cancer screening: why modelling is essential.

Authors:  Kevin Ten Haaf; Harry J de Koning
Journal:  J Epidemiol Community Health       Date:  2015-06-12       Impact factor: 3.710

Review 5.  Radiomics: extracting more information from medical images using advanced feature analysis.

Authors:  Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts
Journal:  Eur J Cancer       Date:  2012-01-16       Impact factor: 9.162

6.  MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Brigitte Dreno; John F Thompson; Bernard Mark Smithers; Mario Santinami; Thomas Jouary; Ralf Gutzmer; Evgeny Levchenko; Piotr Rutkowski; Jean-Jacques Grob; Sergii Korovin; Kamil Drucis; Florent Grange; Laurent Machet; Peter Hersey; Ivana Krajsova; Alessandro Testori; Robert Conry; Bernard Guillot; Wim H J Kruit; Lev Demidov; John A Thompson; Igor Bondarenko; Jaroslaw Jaroszek; Susana Puig; Gabriela Cinat; Axel Hauschild; Jelle J Goeman; Hans C van Houwelingen; Fernando Ulloa-Montoya; Andrea Callegaro; Benjamin Dizier; Bart Spiessens; Muriel Debois; Vincent G Brichard; Jamila Louahed; Patrick Therasse; Channa Debruyne; John M Kirkwood
Journal:  Lancet Oncol       Date:  2018-06-13       Impact factor: 41.316

7.  Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study.

Authors:  Giulia Veronesi; Patrick Maisonneuve; Massimo Bellomi; Cristiano Rampinelli; Iara Durli; Raffaella Bertolotti; Lorenzo Spaggiari
Journal:  Ann Intern Med       Date:  2012-12-04       Impact factor: 25.391

Review 8.  Cancer overdiagnosis: a biological challenge and clinical dilemma.

Authors:  Sudhir Srivastava; Eugene J Koay; Alexander D Borowsky; Angelo M De Marzo; Sharmistha Ghosh; Paul D Wagner; Barnett S Kramer
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

9.  Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening.

Authors:  Jaileene Pérez-Morales; Ilke Tunali; Olya Stringfield; Steven A Eschrich; Yoganand Balagurunathan; Robert J Gillies; Matthew B Schabath
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

10.  Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial.

Authors:  Matthew B Schabath; Pierre P Massion; Zachary J Thompson; Steven A Eschrich; Yoganand Balagurunathan; Dmitry Goldof; Denise R Aberle; Robert J Gillies
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.